Comirnaty (BNT162b2) from BioNTech SE (NASDAQ:BNTX) and Pfizer Inc. (NYSE:PFE) received provisional approval from the Australian Therapeutic Goods Administration and emergency use authorization from the Food and Health Bureau of the Hong Kong Special Administrative Region...

Near the end of a year when most of Gilead’s over $30 billion in deals were in cancer, the company’s latest billion-dollar acquisition showed an appetite for growth in its area of greatest historical strength:...

ASH data presented by VelosBio — which drove the latest in a string of high wattage ADC deals — is building confidence in a target valued for its potential in both solid and hematological cancers. While...

This year’s ASH meeting provides an opportunity to take stock of clinical progress in hot target, modality and disease areas: CD47 inhibitors, allogeneic CAR T cells and sickle cell disease. Abstracts...

Delay for Spectrum due to COVID-19 travel restrictionsSpectrum Pharmaceuticals Inc. (NASDAQ:SPPI) said FDA is deferring action on the company’s BLA for its Rolontis eflapegrastim because the agency was unable to inspect Hanmi Bioplant, the drug substance...

A pair of deals with Merck on Monday gives Seattle Genetics $1.7 billion in cash before counting any milestones, enough to bring additional cancer programs or ADC technologies into the fold via in-licensing...

Chinook hooks $106M, soon to test NASDAQ’s watersChinook Therapeutics Inc. raised $106 million in a venture round as it prepares to reverse-merge with Aduro Biotech Inc. (NASDAQ:ADRO). New investors in the kidney disease company include...

Less than four months after launching with $30 million, Taysha has closed a $95 million series B to advance its lead CNS gene therapy programs into the clinic and build a commercially scalable GMP manufacturing...

Jnana is developing small molecules against a relatively untapped class of proteins -- solute carriers -- to modulate cell metabolism. On Tuesday, the biotech closed its first deal with a large biopharma, partnering with Roche...

After a drug repositioning screen flagged Verge’s ALS target PIKFYVE as an Achilles heel for COVID-19, the neurodegeneration-focused biotech jumped into infectious disease by tapping the growing ecosystem of partners with industrialized SARS-CoV-2 assays. That...